vs
Side-by-side financial comparison of DIODES INC (DIOD) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
DIODES INC is the larger business by last-quarter revenue ($391.6M vs $281.3M, roughly 1.4× Guardant Health, Inc.). DIODES INC runs the higher net margin — 2.6% vs -45.7%, a 48.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 15.4%). DIODES INC produced more free cash flow last quarter ($12.4M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 13.9%).
Diodes Incorporated is a global semiconductor manufacturer that designs, produces and supplies discrete, analog and mixed-signal semiconductor products. Its solutions serve key end markets including automotive, industrial, consumer electronics, personal computing and communications infrastructure, with a worldwide customer base.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
DIOD vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $391.6M | $281.3M |
| Net Profit | $10.2M | $-128.5M |
| Gross Margin | 31.1% | 64.6% |
| Operating Margin | 3.4% | -43.0% |
| Net Margin | 2.6% | -45.7% |
| Revenue YoY | 15.4% | 39.4% |
| Net Profit YoY | 23.8% | -15.8% |
| EPS (diluted) | $0.23 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $391.6M | $281.3M | ||
| Q3 25 | $392.2M | $265.2M | ||
| Q2 25 | $366.2M | $232.1M | ||
| Q1 25 | $332.1M | $203.5M | ||
| Q4 24 | $339.3M | $201.8M | ||
| Q3 24 | $350.1M | $191.5M | ||
| Q2 24 | $319.8M | $177.2M | ||
| Q1 24 | $302.0M | $168.5M |
| Q4 25 | $10.2M | $-128.5M | ||
| Q3 25 | $14.3M | $-92.7M | ||
| Q2 25 | $46.1M | $-99.9M | ||
| Q1 25 | $-4.4M | $-95.2M | ||
| Q4 24 | $8.2M | $-111.0M | ||
| Q3 24 | $13.7M | $-107.8M | ||
| Q2 24 | $8.0M | $-102.6M | ||
| Q1 24 | $14.0M | $-115.0M |
| Q4 25 | 31.1% | 64.6% | ||
| Q3 25 | 30.7% | 64.7% | ||
| Q2 25 | 31.5% | 65.0% | ||
| Q1 25 | 31.5% | 63.3% | ||
| Q4 24 | 32.7% | 61.6% | ||
| Q3 24 | 33.7% | 61.1% | ||
| Q2 24 | 33.6% | 59.1% | ||
| Q1 24 | 33.0% | 61.2% |
| Q4 25 | 3.4% | -43.0% | ||
| Q3 25 | 3.0% | -37.3% | ||
| Q2 25 | 2.6% | -45.9% | ||
| Q1 25 | 0.4% | -54.6% | ||
| Q4 24 | 3.5% | -62.4% | ||
| Q3 24 | 6.2% | -61.3% | ||
| Q2 24 | 1.2% | -56.8% | ||
| Q1 24 | 4.3% | -59.2% |
| Q4 25 | 2.6% | -45.7% | ||
| Q3 25 | 3.6% | -35.0% | ||
| Q2 25 | 12.6% | -43.0% | ||
| Q1 25 | -1.3% | -46.8% | ||
| Q4 24 | 2.4% | -55.0% | ||
| Q3 24 | 3.9% | -56.3% | ||
| Q2 24 | 2.5% | -57.9% | ||
| Q1 24 | 4.6% | -68.2% |
| Q4 25 | $0.23 | $-1.01 | ||
| Q3 25 | $0.31 | $-0.74 | ||
| Q2 25 | $0.99 | $-0.80 | ||
| Q1 25 | $-0.10 | $-0.77 | ||
| Q4 24 | $0.18 | $-0.90 | ||
| Q3 24 | $0.30 | $-0.88 | ||
| Q2 24 | $0.17 | $-0.84 | ||
| Q1 24 | $0.30 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $377.0M | $378.2M |
| Total DebtLower is stronger | $25.7M | $1.5B |
| Stockholders' EquityBook value | $1.9B | $-99.3M |
| Total Assets | $2.4B | $2.0B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $377.0M | $378.2M | ||
| Q3 25 | $386.4M | $580.0M | ||
| Q2 25 | $327.3M | $629.1M | ||
| Q1 25 | $343.9M | $698.6M | ||
| Q4 24 | $316.1M | $525.5M | ||
| Q3 24 | $319.3M | $585.0M | ||
| Q2 24 | $273.9M | $933.7M | ||
| Q1 24 | $276.0M | $1.0B |
| Q4 25 | $25.7M | $1.5B | ||
| Q3 25 | $24.9M | $1.1B | ||
| Q2 25 | $26.4M | $1.1B | ||
| Q1 25 | $20.5M | $1.1B | ||
| Q4 24 | $20.7M | $1.1B | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | $20.3M | — | ||
| Q1 24 | $20.9M | — |
| Q4 25 | $1.9B | $-99.3M | ||
| Q3 25 | $1.9B | $-354.5M | ||
| Q2 25 | $1.9B | $-305.5M | ||
| Q1 25 | $1.8B | $-250.8M | ||
| Q4 24 | $1.8B | $-139.6M | ||
| Q3 24 | $1.8B | $-60.1M | ||
| Q2 24 | $1.8B | $-1.6M | ||
| Q1 24 | $1.7B | $68.3M |
| Q4 25 | $2.4B | $2.0B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.4B | $1.6B | ||
| Q1 24 | $2.4B | $1.7B |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.1M | $-26.4M |
| Free Cash FlowOCF − Capex | $12.4M | $-54.2M |
| FCF MarginFCF / Revenue | 3.2% | -19.3% |
| Capex IntensityCapex / Revenue | 6.6% | 9.9% |
| Cash ConversionOCF / Net Profit | 3.74× | — |
| TTM Free Cash FlowTrailing 4 quarters | $137.2M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.1M | $-26.4M | ||
| Q3 25 | $79.1M | $-35.4M | ||
| Q2 25 | $41.5M | $-60.3M | ||
| Q1 25 | $56.7M | $-62.7M | ||
| Q4 24 | $81.8M | $-64.5M | ||
| Q3 24 | $54.4M | $-51.1M | ||
| Q2 24 | $14.4M | $-94.0M | ||
| Q1 24 | $-31.1M | $-30.3M |
| Q4 25 | $12.4M | $-54.2M | ||
| Q3 25 | $62.8M | $-45.8M | ||
| Q2 25 | $21.1M | $-65.9M | ||
| Q1 25 | $40.8M | $-67.1M | ||
| Q4 24 | $62.1M | $-83.4M | ||
| Q3 24 | $39.4M | $-55.3M | ||
| Q2 24 | $-3.5M | $-99.1M | ||
| Q1 24 | $-51.5M | $-37.2M |
| Q4 25 | 3.2% | -19.3% | ||
| Q3 25 | 16.0% | -17.3% | ||
| Q2 25 | 5.8% | -28.4% | ||
| Q1 25 | 12.3% | -33.0% | ||
| Q4 24 | 18.3% | -41.3% | ||
| Q3 24 | 11.2% | -28.9% | ||
| Q2 24 | -1.1% | -55.9% | ||
| Q1 24 | -17.1% | -22.1% |
| Q4 25 | 6.6% | 9.9% | ||
| Q3 25 | 4.2% | 3.9% | ||
| Q2 25 | 5.6% | 2.4% | ||
| Q1 25 | 4.8% | 2.2% | ||
| Q4 24 | 5.8% | 9.4% | ||
| Q3 24 | 4.3% | 2.2% | ||
| Q2 24 | 5.6% | 2.9% | ||
| Q1 24 | 6.7% | 4.1% |
| Q4 25 | 3.74× | — | ||
| Q3 25 | 5.54× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 9.93× | — | ||
| Q3 24 | 3.95× | — | ||
| Q2 24 | 1.80× | — | ||
| Q1 24 | -2.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
